CN110638845B - Bacterium composition and application thereof to functional milk powder for improving anorexia - Google Patents
Bacterium composition and application thereof to functional milk powder for improving anorexia Download PDFInfo
- Publication number
- CN110638845B CN110638845B CN201911085754.0A CN201911085754A CN110638845B CN 110638845 B CN110638845 B CN 110638845B CN 201911085754 A CN201911085754 A CN 201911085754A CN 110638845 B CN110638845 B CN 110638845B
- Authority
- CN
- China
- Prior art keywords
- parts
- lactobacillus helveticus
- weight
- composite microbial
- rhamnoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000843 powder Substances 0.000 title claims abstract description 21
- 241000894006 Bacteria Species 0.000 title claims description 5
- 206010061428 decreased appetite Diseases 0.000 title description 16
- 208000022531 anorexia Diseases 0.000 title description 15
- 239000000203 mixture Substances 0.000 title description 7
- 235000020604 functional milk Nutrition 0.000 title description 5
- 240000002605 Lactobacillus helveticus Species 0.000 claims abstract description 33
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims abstract description 27
- 229940054346 lactobacillus helveticus Drugs 0.000 claims abstract description 27
- 239000002245 particle Substances 0.000 claims abstract description 22
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 20
- 239000002131 composite material Substances 0.000 claims abstract description 19
- 239000002068 microbial inoculum Substances 0.000 claims abstract description 17
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 11
- 229930006000 Sucrose Natural products 0.000 claims abstract description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 10
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 10
- 239000001488 sodium phosphate Substances 0.000 claims abstract description 10
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims abstract description 10
- 229910000406 trisodium phosphate Inorganic materials 0.000 claims abstract description 10
- 235000019801 trisodium phosphate Nutrition 0.000 claims abstract description 10
- 239000000230 xanthan gum Substances 0.000 claims abstract description 10
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 10
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 10
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 10
- 230000001580 bacterial effect Effects 0.000 claims abstract description 5
- 239000005720 sucrose Substances 0.000 claims description 9
- 239000001963 growth medium Substances 0.000 claims description 7
- 230000012010 growth Effects 0.000 claims description 5
- 230000000813 microbial effect Effects 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 3
- 238000012136 culture method Methods 0.000 claims description 3
- 238000000855 fermentation Methods 0.000 claims description 3
- 230000004151 fermentation Effects 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000009630 liquid culture Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000002054 inoculum Substances 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 235000013365 dairy product Nutrition 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 abstract description 6
- 229960004793 sucrose Drugs 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 238000002156 mixing Methods 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 210000002784 stomach Anatomy 0.000 description 11
- 239000000463 material Substances 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 238000007873 sieving Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 235000012631 food intake Nutrition 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 241000606750 Actinobacillus Species 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000321 herbal drug Substances 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 150000008265 rhamnosides Chemical class 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- DJSISFGPUUYILV-UHFFFAOYSA-N UNPD161792 Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- NPLTVGMLNDMOQE-UHFFFAOYSA-N carthamidin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=C(O)C(O)=C2C(=O)C1 NPLTVGMLNDMOQE-UHFFFAOYSA-N 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000001991 scapula Anatomy 0.000 description 2
- DJSISFGPUUYILV-ZFORQUDYSA-N scutellarin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-ZFORQUDYSA-N 0.000 description 2
- 229930190376 scutellarin Natural products 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 240000005717 Dioscorea alata Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000549954 Gymnema yunnanense Species 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000244269 Peucedanum Species 0.000 description 1
- 244000134540 Polymnia sonchifolia Species 0.000 description 1
- 235000003406 Polymnia sonchifolia Nutrition 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000220151 Saxifragaceae Species 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 235000015138 kumis Nutrition 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1322—Inorganic compounds; Minerals, including organic salts thereof, oligo-elements; Amino-acids, peptides, protein-hydrolysates or derivatives; Nucleic acids or derivatives; Yeast extract or autolysate; Vitamins; Antibiotics; Bacteriocins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/147—Helveticus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Abstract
The invention discloses a composite microbial inoculum particle, which comprises the following formula of lactobacillus helveticus bacterial powder (5-10 parts by weight), 3, 4-dihydroxy benzoic acid-3-O- α -L-rhamnoside (3-5 parts by weight), magnesium stearate (1-2 parts by weight), anhydrous trisodium phosphate (2-3 parts by weight), hydroxypropyl methylcellulose (5-10 parts by weight), xanthan gum (1-3 parts by weight) and cane sugar (200 parts by weight).
Description
Technical Field
The invention relates to a bactericide composition and application thereof, in particular to a bactericide composition and application thereof to functional milk powder for improving anorexia.
Background
The human body inhabits numerous microorganisms, with the micro-ecosystem being the most dominant, most complex system. When the immunity of a human is reduced, probiotics play an important role in human health. This view has been confirmed in sterile rodents and birds. Microbial colonization plays an important role in nutrition, in vivo growth, induction and regulation of immune and endocrine balance, maturation of the central nervous system and behavior. At present, the largest ecological site of the microbial community is the intestinal tract of human beings, and the structure and diversity of the intestinal microecology play a vital role in the health of human beings and animals. Bacteria of the stomach are also very important. The pH value of gastric acid is low, bacteria can reach the intestinal tract through the stomach, the intestinal tract can play a role in absorption, and when the microecological structure or diversity of the gastrointestinal tract is disordered, various diseases can be caused.
Anorexia is a long-term loss of appetite and appetite caused by various reasons, and then gradually causes emaciation, slow development of intelligence and reduced immunity, is a disease which is easy to cause various diseases and is a common disease and frequently encountered disease. According to the traditional Chinese medicine, the pathological viscera mainly comprise spleen and stomach, the pathogenesis of the pathological viscera is that the spleen fails to transport and transform, the spleen and the stomach are mutually exterior and interior, the spleen governs transportation and transformation, the stomach governs accepting, the spleen fails to harmonize with the stomach, and the stomach fails to eat. Therefore, in terms of treatment, the basic principle of regulating the spleen and stomach is mostly adopted, and the microorganisms have important biological and medical significance for the experiments of gastric emptying and small intestine propulsion and the discussion of the improvement of the digestion function.
The invention aims to provide composite microbial inoculum particles effective on anorexia.
Disclosure of Invention
The invention aims to provide composite microbial inoculum particles effective for anorexia.
Lactobacillus helveticus (L Acobacillus helveticus), first isolated from western cheese, Lactobacillus, 0.6-1.0x2.0-6.0 microns, singly or in strands, stained with methine blue without contaminating particles (this is different from Lactobacillus delbrueckii, Lactobacillus bulgaricus, Lactobacillus lisi, and Lactobacillus lactis), on agar plates, the colony diameter is 2-3 mm or less, generally opaque, white to light gray, rough to pseudorhizoid, anaerobic and 5% CO2The growth of yacon streak culture under the condition is greatly increased, and the colony is larger or smoother in a culture medium containing Tween 80 or sodium oleate.
The lactobacillus helveticus (L actinobacillus helveticus) NS8 selected in the embodiment of the present invention was isolated from Koumiss in the region of Silibinoguole and purchased as a commercially available product.
The Asian peltate yam rhizome (AspidopterysobcordiataHemsl.) is a woody vine of the genus Astrocarya of the family Saxifragaceae, and is mainly distributed in shrubs at forest edges of high-altitude mountainous regions in Hainan, Yunnan and other regions of China. The number of the plants is 20 in the world, and about 8 in China, wherein two kinds of plants are used for medicine. Leaves of Guizhou guinii (a. calvalerieilevl.) are used as a medicine for treating infantile malnutrition. The Peucedanum comprises stems of various Gymnema Yunnanense Tsiang, radix Stephaniae Sinicae is used as medicine, has astringent and cool properties, has the effects of diminishing inflammation, promoting urination, clearing heat and removing urinary calculus, and is mainly used for treating urinary tract infection, cystitis, lithangiuria, rheumatic osteodynia, postpartum asthenia, inappetence and other diseases.
Raja et al have planar structure of 3, 4-dihydroxybenzoic acid-3-O- α -L-rhamnoside from 1 new rhamnoside (Chinese herbal medicine Chinese Traditional and Herbal Drugs, 50 th volume, 5 th year, 3 th month, 2019 th month, etc.) in radix Stephaniae Sinicae.
The inventor finds that the 3, 4-dihydroxy-benzoic acid-3-O- α -L-rhamnoside and lactobacillus helveticus (L actinobacillus helveticus) NS8 have the effect of synergistically improving anorexia.
The technical problem to be solved by the invention can be realized by the following technical scheme.
A composite microbial agent particle, comprising:
lactobacillus helveticus, 3, 4-dihydroxybenzoic acid-3-O- α -L-rhamnoside.
Preferably, the lactobacillus helveticus is lactobacillus helveticus ns8 (L actinobacillus helveticus) NS8 is isolated from koumis in the region of sulindac guo, and is isolated, identified and stored by the psychohealth focus laboratory behavioral biology laboratory of the academy of sciences of china, and is a commercially available product.
The culture method of the lactobacillus helveticus NS8 comprises the following steps: inoculating a ring of lactobacillus to MRS solid culture medium, streaking, and performing anaerobic culture at 37 ℃ for 24 h. Selecting single colony with better growth in the plate, inoculating the single colony into MRS liquid culture medium for activation, and performing anaerobic culture to obtain 5 x 107(CFU/ml) Lactobacillus helveticus NS8 seed fluid. Gradually amplifying the seed liquid of the lactobacillus helveticus NS8 to a large tank for fermentation, centrifuging, and freeze-drying to obtain the bacterial powder.
The 3, 4-dihydroxy-benzoic acid-3-O- α -L-rhamnoside is obtained by separating and extracting the scutellarin from the scapula obovata according to the method of the reference document (1 new rhamnoside in the pterosporium obovata, Chinese Herbal medicine Chinese Traditional and Herbal Drugs Vol.50, 3 months 2019).
The formula of the composite microbial inoculum particle is as follows:
lactobacillus helveticus bacterium powder (5-10 parts by weight), 3, 4-dihydroxy benzoic acid-3-O- α -L-rhamnoside (3-5 parts by weight), magnesium stearate (1-2 parts by weight), anhydrous trisodium phosphate (2-3 parts by weight), hydroxypropyl methylcellulose (5-10 parts by weight), xanthan gum (1-3 parts by weight) and sucrose (200 parts by weight).
The preparation method comprises the following steps:
(1) preparing materials, namely screening various materials through a 40-mesh sieve for later use.
(2) Sugar particle preparation: adding sucrose (200 parts by weight) and xanthan gum (1-3 parts by weight) into a horizontal mixer, mixing for 15 minutes, adding purified water, stirring, placing on a swing granulator, sieving with a 30-mesh sieve, granulating, drying wet granules in a dryer, and controlling the actual temperature to be 40-60 ℃; the dried granules were sieved through a 30 mesh sieve. The moisture should not exceed 1.5%.
(3) The preparation method of the composite microbial inoculum comprises the steps of putting lactobacillus helveticus bacterium powder (5-10 parts by weight), 3, 4-dihydroxy benzoic acid-3-O- α -L-rhamnoside (3-5 parts by weight) and hydroxypropyl methylcellulose (5-10 parts by weight) into a horizontal mixer, starting stirring, mixing uniformly, adding a proper amount of water, stirring for 30min, sieving particles with a 30-mesh sieve, grading, and drying for 30min at 35-40 ℃.
(4) Total mixing: mixing the composite microbial inoculum particles, magnesium stearate (1-2 parts by weight) and anhydrous trisodium phosphate (2-3 parts by weight) for 30-60 minutes.
The invention has the advantages that:
the inventor finds that the 3, 4-dihydroxy-benzoic acid-3-O- α -L-rhamnoside can act on the stomach synergistically with lactobacillus helveticus (L actinobacillus helveticus) NS8, and has the effect of synergistically improving anorexia.
Detailed Description
The following examples of the present invention are described in detail, and are only for the purpose of illustrating the present invention and are not to be construed as limiting the present invention.
Specific examples of the present invention are described below.
Preparation of lactobacillus helveticus NS8 bacterial powder:
the culture method of the lactobacillus helveticus NS8 comprises the following steps: inoculating a ring of lactobacillus to MRS solid culture medium, streaking, and performing anaerobic culture at 37 ℃ for 24 h. Selecting single colony with better growth in the plate, inoculating the single colony into MRS liquid culture medium for activation, and performing anaerobic culture to obtain 5 x 107(CFU/ml) Lactobacillus helveticus NS8 seed fluid. Gradually amplifying the seed liquid of the lactobacillus helveticus NS8 to a large tank for fermentation, centrifuging, and freeze-drying to obtain the bacterial powder.
3, 4-dihydroxy-benzoic acid-3-O- α -L-rhamnoside preparation:
the 3, 4-dihydroxy-benzoic acid-3-O- α -L-rhamnoside is obtained by separating and extracting the scutellarin from the scapula obovata according to the method of the reference document (1 new rhamnoside in the pterosporium obovata, Chinese Herbal medicine Chinese Traditional and Herbal Drugs Vol.50, 3 months 2019).
Example 1:
the prescription of the composite microbial inoculum particles is as follows:
lactobacillus helveticus bacterium powder (5 parts by weight), 3, 4-dihydroxybenzoic acid-3-O- α -L-rhamnoside (5 parts by weight), magnesium stearate (1 part by weight), anhydrous trisodium phosphate (3 parts by weight), hydroxypropyl methylcellulose (10 parts by weight), xanthan gum (1 part by weight), sucrose (200 parts by weight)
The preparation method comprises the following steps:
(1) preparing materials, namely screening various materials through a 40-mesh sieve for later use.
(2) Sugar particle preparation: adding sucrose and xanthan gum into a horizontal mixer, mixing for 15 minutes, adding purified water, stirring, placing on a swing granulator, sieving with a 30-mesh sieve, granulating, drying wet granules in a dryer, and controlling the actual temperature at 40 ℃; the dried granules were sieved through a 30 mesh sieve. The moisture should not exceed 1.5%.
(3) The preparation method of the composite microbial inoculum comprises putting Lactobacillus helveticus powder, 3, 4-dihydroxy benzoic acid-3-O- α -L-rhamnoside, and hydroxypropyl methylcellulose into a horizontal mixer, stirring, adding appropriate amount of water, stirring for 30min, sieving with 30 mesh sieve, and drying at 35-40 deg.C for 30 min.
(4) Total mixing: the composite microbial inoculum particles, magnesium stearate and anhydrous trisodium phosphate are mixed for 30 minutes.
Example 2:
the prescription of the composite microbial inoculum particles is as follows:
lactobacillus helveticus bacterium powder (7 parts by weight), 3, 4-dihydroxybenzoic acid-3-O- α -L-rhamnoside (4 parts by weight), magnesium stearate (1 part by weight), anhydrous trisodium phosphate (2 parts by weight), hydroxypropyl methylcellulose (8 parts by weight), xanthan gum (2 parts by weight), sucrose (200 parts by weight)
The preparation method comprises the following steps:
(1) preparing materials, namely screening various materials through a 40-mesh sieve for later use.
(2) Sugar particle preparation: adding sucrose and xanthan gum into a horizontal mixer, mixing for 15 minutes, adding purified water, stirring, placing on a swing granulator, sieving with a 30-mesh sieve, granulating, drying wet granules in a dryer, and controlling the actual temperature to be 40-60 ℃; the dried granules were sieved through a 30 mesh sieve. The moisture should not exceed 1.5%.
(3) The preparation method of the composite microbial inoculum comprises putting Lactobacillus helveticus powder, 3, 4-dihydroxy benzoic acid-3-O- α -L-rhamnoside, and hydroxypropyl methylcellulose into a horizontal mixer, stirring, adding appropriate amount of water, stirring for 30min, sieving with 30 mesh sieve, and drying at 35 deg.C for 30 min.
(4) Total mixing: the complex microbial inoculum particles, magnesium stearate and anhydrous trisodium phosphate are mixed for 50 minutes.
Example 3
The prescription of the composite microbial inoculum particles is as follows:
lactobacillus helveticus bacterium powder (10 parts by weight), 3, 4-dihydroxybenzoic acid-3-O- α -L-rhamnoside (5 parts by weight), magnesium stearate (1 part by weight), anhydrous trisodium phosphate (3 parts by weight), hydroxypropyl methylcellulose (9 parts by weight), xanthan gum (2 parts by weight), sucrose (200 parts by weight)
The preparation method comprises the following steps:
(1) preparing materials, namely screening various materials through a 40-mesh sieve for later use.
(2) Sugar particle preparation: adding sucrose and xanthan gum into a horizontal mixer, mixing for 15 minutes, adding purified water, stirring, placing on a swing granulator, sieving with a 30-mesh sieve, granulating, drying wet granules in a dryer, and controlling the actual temperature at 60 ℃; the dried granules were sieved through a 30 mesh sieve. The moisture should not exceed 1.5%.
(3) The preparation method of the composite microbial inoculum comprises putting Lactobacillus helveticus powder, 3, 4-dihydroxy benzoic acid-3-O- α -L-rhamnoside, and hydroxypropyl methylcellulose into a horizontal mixer, stirring, adding appropriate amount of water, stirring for 30min, sieving with 30 mesh sieve, and drying at 35 deg.C for 30 min.
(4) Total mixing: the composite microbial inoculum particles, magnesium stearate and anhydrous trisodium phosphate are mixed for 60 minutes.
Example 4
Comparative example 1: the same formulation as in example 3, without addition of Lactobacillus helveticus
Comparative example 2 formulation of example 3 without 3, 4-Dihydroxybenzoic acid-3-O- α -L-rhamnoside
Comparative example 3 same formulation as in example 3, without addition of Lactobacillus helveticus, 3, 4-dihydroxybenzoic acid-3-O- α -L-rhamnoside
Example 5
Study of anorexia:
the Wistar white rat is selected for modeling, the model is SPF grade, the male and female are half, and the body mass is 60-75 g.
Grouping animals and establishing an anorexia rat model: 80 white rats are taken and are randomly divided into 8 groups according to physical quality, and each group comprises 10 rats. Feeding special feed for rat anorexia to establish anorexia model (prepared from fish floss, milk powder, white sugar, corn flour, soybean flour, fresh egg, and fresh fat meat at ratio of 1: 2: 1.8: 2), mixing, kneading into biscuit, each block is about 20g, air drying, and refrigerating). All rats were fed individually and were free to drink water. On day 8, the rats in each group were adjusted according to the body mass and food intake of the rats to make the body mass and food intake of the rats in each group uniform.
The 8 groups of rats were respectively an example 1 group, an example 2 group, an example 3 group, a comparative example 1 group, a comparative example 2 group, a comparative example 3 group, a negative control group and a positive control group. Examples and comparative examples were conducted in accordance with 0.3 g.kg-1D dose feeding, feeding with special feed in negative control group, and adding 1.0 g/kg stomach invigorating and digestion promoting tablet in positive control group-1D dose feeding. The model-built rats were continuously fed for another 3 weeks, and the general state of the animals was observed, and the body mass and food intake of the 8 anorexia rats were measured and recorded from week 1 to week 3. The test results are shown in tables 1 and 2 below.
After feeding in week 3, lightly anaesthetizing the animals with diethyl ether, ligating cardia, collecting the whole stomach, carefully collecting gastric juice, centrifuging for 20min at 1000g, sucking supernatant, measuring free acidity, total acidity and pepsin activity, calculating the concentration of free acid and total acid, and calculating formula of free acid (mol. L)-1) Titration of end point consumption as free acidThe number of milliliters of NaOH solution and the total acidity (mmol. L)-1) NaOH ml consumed by two titrations, total acid output (mmol. L)-1) Total acidity × gastric fluid volume per hour the test results are shown in table 3 below.
Table 1: influence on rat body quality (
n＝10)
Table 2: effect on food intake in rats (
n＝10)
Table 3 effect on rat free and total acids: (
n＝10)
From tables 1, 2 and 3, it can be seen that the simultaneous addition of lactobacillus helveticus, 3, 4-dihydroxybenzoic acid-3-O- α -L-rhamnoside can obviously increase the body quality and food consumption (P < 0.05) of mice in a young anorexia model, increase the total acid and free acid content in gastric juice (P < 0.05 compared with negative control in examples 1-3), and the addition of lactobacillus helveticus or 3, 4-dihydroxybenzoic acid-3-O- α -L-rhamnoside alone can slightly increase the body quality and food consumption, and the total acid and free acid content (compared with negative control in comparative examples 1-3).
Example 6
Preparing functional milk powder:
and uniformly mixing 90 parts of milk powder and 10 parts of composite microbial inoculum particles to prepare the functional milk powder with the effect of improving anorexia.
It is to be understood that the foregoing is only a preferred embodiment of the invention and that modifications, variations and changes may be made in the invention without departing from the spirit or scope of the invention as defined in the appended claims.
In the description herein, references to the description of the term "one embodiment," "some embodiments," "an example," "a specific example," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above do not necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
While embodiments of the invention have been shown and described, it will be understood by those of ordinary skill in the art that: various changes, modifications, substitutions and alterations can be made to the embodiments without departing from the principles and spirit of the invention, the scope of which is defined by the claims and their equivalents.
Claims (3)
1. The composite microbial inoculum particles are characterized by comprising the following specific components:
5-10 parts of lactobacillus helveticus bacterium powder, 4-5 parts of 3, 4-dihydroxybenzoic acid-3-O- α -L-rhamnoside, 1-2 parts of magnesium stearate, 2-3 parts of anhydrous trisodium phosphate, 5-10 parts of hydroxypropyl methyl cellulose, 1-3 parts of xanthan gum and 200 parts of sucrose;
wherein the lactobacillus helveticus is lactobacillus helveticus NS 8.
2. The composite microbial inoculant particle of claim 1, wherein lactobacillus helveticus NS8 culture method:
inoculating a ring of lactic acid bacteria into an MRS solid culture medium, streaking, and carrying out anaerobic culture at 37 ℃ for 24 h;
selecting single colony with better growth in the plate, inoculating the single colony in MRS liquid culture medium for activation, and performing anaerobic culture to obtain 5 × 107CFU/ml of Lactobacillus helveticus NS8 seed fluid;
gradually amplifying the seed liquid of the lactobacillus helveticus NS8 to a large tank for fermentation, centrifuging, and freeze-drying to obtain the bacterial powder.
3. A dairy product comprising the composite microbial inoculant particles of claim 1 or 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911085754.0A CN110638845B (en) | 2019-11-08 | 2019-11-08 | Bacterium composition and application thereof to functional milk powder for improving anorexia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911085754.0A CN110638845B (en) | 2019-11-08 | 2019-11-08 | Bacterium composition and application thereof to functional milk powder for improving anorexia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110638845A CN110638845A (en) | 2020-01-03 |
| CN110638845B true CN110638845B (en) | 2020-07-14 |
Family
ID=69014312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911085754.0A Active CN110638845B (en) | 2019-11-08 | 2019-11-08 | Bacterium composition and application thereof to functional milk powder for improving anorexia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110638845B (en) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5312591B2 (en) * | 1974-04-10 | 1978-05-02 | ||
| ES2608651T3 (en) * | 2009-05-11 | 2017-04-12 | Nestec S.A. | Lactobacillus johnsonii La1 NCC533 (CNCM I-1225), non-replicating, and immune disorders |
| EP2335502A1 (en) * | 2009-12-07 | 2011-06-22 | Nestec S.A. | An infant formula delivery system comprising probiotics and an infant nutritional formulation |
| CN107118981A (en) * | 2017-04-28 | 2017-09-01 | 广东格物生物科技有限公司 | A kind of probiotics preparation and its application for being used to nurse one's health enteric microorganism environment |
| EP3657956A4 (en) * | 2017-07-24 | 2020-12-30 | North Carolina State University | Compositions and methods for increasing phytochemical bioavailablity and bioactivity |
| CN109172615A (en) * | 2018-09-07 | 2019-01-11 | 北京金锋实验室科技有限公司 | For treating the probiotics of self-closing disease patient |
| CN109157547A (en) * | 2018-09-07 | 2019-01-08 | 北京金锋实验室科技有限公司 | For treating the lactic acid bacteria composite fungicide of depression |
| CN110192653A (en) * | 2019-05-22 | 2019-09-03 | 唐山创盈企业管理咨询有限公司 | A kind of preparation method of pregnant and lying-in women and children special-purpose probiotics |
-
2019
- 2019-11-08 CN CN201911085754.0A patent/CN110638845B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110638845A (en) | 2020-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1969657B (en) | Probiotic feed additive used for pig | |
| ES2294266T3 (en) | DIETETIC AND / OR PHARMACEUTICAL COMPOSITIONS TO BE USED BY HUMANS AND / OR ANIMALS BASED ON PROBIOTIC MICROBIAL PREPARATIONS. | |
| CN103005159A (en) | Preparation method of ginkgo leaf biological feed additive | |
| CN104770575B (en) | A kind of Radix Astragali probiotics and its preparation method and application | |
| CN107746818B (en) | A kind of compound probiotic agent and preparation method thereof improving intestines function of piglings | |
| CN107744061A (en) | Feed addictive, its preparation method and application and the feed containing the feed addictive | |
| CN113616715B (en) | Fermented traditional Chinese medicine oral liquid for treating piglet diarrhea and improving intestinal flora thereof | |
| CN107296164A (en) | A kind of preparation method for the Traditional Chinese medicine probiotic fermentating metabolism product for preventing and treating piglet bacillary diarrhoea | |
| CN107629981B (en) | A kind of compound probiotic agent and preparation method thereof improving chick function of intestinal canal | |
| CN109486732A (en) | A kind of bifidobacterium longum and its application | |
| CN108850606A (en) | A kind of feed addictive and the preparation method and application thereof for improving piglet immunological function and improving intestinal microflora | |
| CN110638845B (en) | Bacterium composition and application thereof to functional milk powder for improving anorexia | |
| US20210177028A1 (en) | Improved human food product | |
| RU2348174C1 (en) | Fodder additive for sucking period piglets | |
| CN109481540A (en) | Composition and its preparation method and application for preventing and treating mammitis of animal | |
| CN109221697A (en) | Weaned piglets probiotic feed and preparation method thereof | |
| CN106889615B (en) | Microelement selenium dietary supplement with function of regulating intestinal flora and application thereof | |
| CN108850613A (en) | Fattening pannage and preparation method thereof | |
| CN107468721A (en) | It is a kind of that there is raising immunity, the probiotics compound for adjusting stomach, weight losing function and its preparation method and application | |
| CN107080045A (en) | A kind of healthy pig feed of the cultivation containing chlorella and preparation method | |
| CN102640847B (en) | Biologic protein feed and preparation method thereof | |
| CN109588584A (en) | A kind of immunologic pattern Larimichthys crocea biological fermentation feed and application thereof | |
| CN108719583A (en) | A kind of feeding complex microorganism additive | |
| RU2779603C1 (en) | Feed additive with phytoprobiotic activity for the prevention and treatment of poultry diseases | |
| CN114711363B (en) | Cherry and green plum solid beverage with healthy flavor and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20200623 Address after: 332000 Xiushui county (Jiujiang) Industrial Park, Jiujiang City, Jiangxi Province Applicant after: AUSNUOTORE NUTRIMENT Co.,Ltd. Address before: Room 612-13, No. 2999 Ziyang Avenue, Nanchang High-tech Industrial Development Zone, Nanchang City, Jiangxi Province Applicant before: Nanchang Norway Pharmaceutical Technology Co.,Ltd. Applicant before: AUSNUOTORE NUTRIMENT Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |